Debt-to-equity in % of NovoCure Ltd from Q2 2016 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
NovoCure Ltd quarterly Debt-to-equity history and change rate from Q2 2016 to Q3 2025.
  • NovoCure Ltd Debt-to-equity for the quarter ending 30 Sep 2025 was 261%, a 15.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

NovoCure Ltd Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 261% +35% +16% 30 Sep 2025
Q2 2025 246% +33% +15% 30 Jun 2025
Q1 2025 241% +42% +21% 31 Mar 2025
Q4 2024 233% +44% +23% 31 Dec 2024
Q3 2024 226% +48% +27% 30 Sep 2024
Q2 2024 213% +42% +25% 30 Jun 2024
Q1 2024 199% +31% +19% 31 Mar 2024
Q4 2023 188% +23% +14% 31 Dec 2023
Q3 2023 178% +11% +6.4% 30 Sep 2023
Q2 2023 171% +2% +1.3% 30 Jun 2023
Q1 2023 167% -5% -2.8% 31 Mar 2023
Q4 2022 165% -13% -7% 31 Dec 2022
Q3 2022 167% +5% +3.4% 30 Sep 2022
Q2 2022 169% +34% +25% 30 Jun 2022
Q1 2022 172% +56% +48% 31 Mar 2022
Q4 2021 178% +83% +88% 31 Dec 2021
Q3 2021 161% +74% +84% 30 Sep 2021
Q2 2021 135% +22% +19% 30 Jun 2021
Q1 2021 116% -10% -8% 31 Mar 2021
Q4 2020 94% -51% -35% 31 Dec 2020
Q3 2020 88% -78% -47% 30 Sep 2020
Q2 2020 113% -66% -37% 30 Jun 2020
Q1 2020 126% -60% -32% 31 Mar 2020
Q4 2019 145% -40% -21% 31 Dec 2019
Q3 2019 165% -2% -1.2% 30 Sep 2019
Q2 2019 179% +25% +16% 30 Jun 2019
Q1 2019 187% +47% +34% 31 Mar 2019
Q4 2018 185% +65% +54% 31 Dec 2018
Q3 2018 167% +56% +51% 30 Sep 2018
Q2 2018 154% +54% +54% 30 Jun 2018
Q1 2018 140% +63% +82% 31 Mar 2018
Q4 2017 120% +64% +115% 31 Dec 2017
Q3 2017 111% +73% +190% 30 Sep 2017
Q2 2017 100% +70% +237% 30 Jun 2017
Q1 2017 77% 31 Mar 2017
Q4 2016 56% 31 Dec 2016
Q3 2016 38% 30 Sep 2016
Q2 2016 30% 30 Jun 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.